Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study - Takeaways - MDSpire

Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study

  • By

  • Youran Li

  • Xiaomei Sun

  • Ke Wen

  • Lu Lu

  • Wei Wang

  • Minna Wu

  • Jiaze Ma

  • Zailong Zhou

  • Yunfei Gu

  • July 10, 2026

  • 0 min

Share

  • 1

    Ustekinumab (UST) was evaluated in a multicenter study involving 163 patients with perianal fistulizing Crohn's disease (pfCD) from 2020 to 2023.

  • 2

    The study reported a fistula response rate of 88.3% and a clinical remission rate of 70.1% at the final follow-up.

  • 3

    Significant improvements in inflammatory biomarkers and hemoglobin levels were observed, with all changes statistically significant (p < 0.001).

  • 4

    Independent predictors of fistula healing included definitive surgery and fewer prior biologic treatments, with a developed nomogram for outcome prediction.

  • 5

    UST was well-tolerated with a low adverse event rate of 7.4% and no severe safety issues reported during the study.

Original Source(s)

Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study

  • by Youran Li, Xiaomei Sun, Ke Wen, Lu Lu, Wei Wang, Minna Wu, Jiaze Ma, Zailong Zhou, Yunfei Gu

  • July 10, 2026

Related Content

AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation

Mechanistic remodeling and immunoregulatory functions of the B cell–humoral immunity axis in inflammatory bowel disease

Host–microbial co-metabolites: from biogenesis to immunomodulation and implications for health and disease